Horse
Clenbuterol
Tissue
MRL
Year of Adoption
Note
Fat
0.2 µg/kg
2003
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Tissue
Fat
MRL
0.2 µg/kg
Year of Adoption
2003
Note
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Kidney
0.6 µg/kg
2003
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Tissue
Kidney
MRL
0.6 µg/kg
Year of Adoption
2003
Note
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Liver
0.6 µg/kg
2003
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Tissue
Liver
MRL
0.6 µg/kg
Year of Adoption
2003
Note
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Muscle
0.2 µg/kg
2003
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Tissue
Muscle
MRL
0.2 µg/kg
Year of Adoption
2003
Note
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
Showing 1 to 4 of 4 entries
Dexamethasone
Tissue
MRL
Year of Adoption
Note
Kidney
1.0 µg/kg
2009
None
Tissue
Kidney
MRL
1.0 µg/kg
Year of Adoption
2009
Note
None
Liver
2.0 µg/kg
2009
None
Tissue
Liver
MRL
2.0 µg/kg
Year of Adoption
2009
Note
None
Muscle
1.0 µg/kg
2009
None
Tissue
Muscle
MRL
1.0 µg/kg
Year of Adoption
2009
Note
None
Showing 1 to 3 of 3 entries
Febantel/Fenbendazole/Oxfendazole
Tissue
MRL
Year of Adoption
Note
Fat
100 µg/kg
1999
None
Tissue
Fat
MRL
100 µg/kg
Year of Adoption
1999
Note
None
Kidney
100 µg/kg
1999
None
Tissue
Kidney
MRL
100 µg/kg
Year of Adoption
1999
Note
None
Liver
500 µg/kg
1999
None
Tissue
Liver
MRL
500 µg/kg
Year of Adoption
1999
Note
None
Muscle
100 µg/kg
1999
None
Tissue
Muscle
MRL
100 µg/kg
Year of Adoption
1999
Note
None